EyePoint Pharmaceuticals (STU:PV3B) EV-to-Revenue : 6.91 (As of Jun. 27, 2025)

EyePoint Pharmaceuticals EV-to-Revenue Chart

EyePoint Pharmaceuticals Annual Data
	Trend	Jun15	Jun16	Jun17	Jun18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-Revenue		Get a 7-Day Free Trial					3.35	6.57	0.50	17.54	3.69

EyePoint Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															14.72	3.91	4.28	3.69	1.41

Competitive Comparison of EyePoint Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, EyePoint Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's EV-to-Revenue falls into.

EyePoint Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

EyePoint Pharmaceuticals's EV-to-Revenue for today is calculated as:

EyePoint Pharmaceuticals's current Enterprise Value is €359.03 Mil.
EyePoint Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €51.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Pharmaceuticals  (STU:PV3B) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EyePoint Pharmaceuticals's PS Ratiofor today is calculated as:

EyePoint Pharmaceuticals's share price for today is €8.898.
EyePoint Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description